Colombian Experience with Transcatheter Aortic Valve Implantation of Medtronic Core Valve

AE Dager, Rutger-jan Nuis, B Caicedo, JA Fonseca, C Arana, L Cruz, LM Benitez, CA Nader, E Duenas, EJ de Marchena, WW O'Neill, Peter de Jaegere

Research output: Contribution to journalArticleAcademicpeer-review


At our institutions, increasing numbers of aortic stenosis patients were not candidates for surgical aortic valve replacement. Accordingly, we initiated the Cali Colombian Transcatheter Aortic Valve Implantation (TAVI) program. From March 2008 through January 2011, 53 consecutive patients (mean age, 79 +/- 6 yr; men, 58%) underwent TAVI with the Medtronic Core Valve System, and data were prospectively collected. Our study's endpoints conformed with Valve Academic Research Consortium recommendations. We report our clinical results. Predicted mortality rates were 25% (interquartile range, 17%-34%) according to logistic EuroSCORE and 6% (interquartile range, 3%-8%) according to the Society of Thoracic Surgeons score. The 30-day mortality rate was 9% (3 intra procedural deaths, 5 total). The combined 30-day safety endpoint was 30% (major vascular sequelae, 23%; life-threatening bleeding, 12%; myocardial infarction, 4%; major stroke, 4%; and acute kidney injury [stage 31, 2%). Eight patients (15%) required post-implantation ba We found that TAVI with the Core Valve prosthesis was safe and feasible, with sustained long-term results, for treating aortic stenosis in patients at excessive surgical risk; nonetheless, serious adverse events occurred in 30% of the patients. (Tex Heart Inst J 2012;39(3):351-8)
Original languageUndefined/Unknown
Pages (from-to)351-358
Number of pages8
JournalTexas Heart Institute Journal
Issue number3
Publication statusPublished - 2012

Cite this